A Prescription Drug User Fee Act target date of May 27, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

A mother has told of her heartbreak at losing both her sons to mitochondrial disease, and her attempts to raise awareness of ...

Researchers have developed a new method for growing T cells in the lab, allowing them to survive longer and fight cancer more effectively. This advancement, detailed in Cell Metabolism, could ...

DCA will be used with a proprietary genetic test to treat an orphan pediatric mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency (PDCD) 1. The FDA granted Priority Review for the NDA and ...

ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to ...

Artificial photosynthesis technology was developed with the addition of the biocatalyst L-alanine dehydrogenase, which combines ammonia with pyruvate to produce L-alanine, to the photoredox system ...

Artificial photosynthesis technology was developed with the addition of the biocatalyst L-alanine dehydrogenase, which combines ammonia with pyruvate to produce L-alanine, to the photoredox system ...